Overview

Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Status:
Recruiting

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Lenvatinib